Aduro Biotech Inc.'s main experimental drug, CRS-207, is a
genetically modified version of the Listeria monocytogenes bacterium.
The company engineers the bacterium so it will stimulate the immune
system to attack tumors instead of causing listeriosis, a potentially
serious food-borne illness. The company is testing CRS-207 and another
experimental "cancer vaccine" called GVAX as a treatment for pancreatic
cancer.
It's also testing CRS-207 as a potential treatment for mesothelioma and is studying other cancer drugs.
The Berkeley, California-based company said its IPO
raised $107.7 million after expenses. Aduro plans to use the proceeds
from the offering to fund clinical trials and for general corporate
purposes.
No comments:
Post a Comment